Adherence with tobramycin inhaled solution and health care utilization
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization. METHODS: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories. RESULTS: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768). CONCLUSIONS: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and individuals collecting four or more courses of nebulised tobramycin per year being 60% less likely to be admitted to hospital than those collecting two or fewer courses (Briesacher 2011).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Briesacher 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169 · cited 2×
“As research in other chronic illnesses has shown, both time and complexity of daily regimen are associated with lower rates of adherence [4], and these observations may also be true for the CF population [5].”
BackgroundIntermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024 · cited 2×
“aeruginosa have had TIS prescribed at least once, although there are no estimates of chronic use [9].”
BackgroundSelf-citationEmerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007 · cited 1×
“aeruginosa infections [7,8].”
Yankaskas, J. R., Marshall, B. C., Sufian, B., Simon, R. H., & Rodman, D. (2004) · Chest · doi:10.1378/chest.125.1_suppl.1s · Cited by 579 · cited 1×
“[14].”
Choo, P. W., Rand, C. S., Inui, T. S., Lee, M.-L. T., Cain, E., Cordeiro-Breault, M., Canning, C., & Platt, R. (1999) · Medical Care · doi:10.1097/00005650-199909000-00002 · Cited by 546 · cited 1×
“However, research has demonstrated predictive validity for measuring the cumulative exposure of medications with acquisition data [25].”
BackgroundClinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
Nixon, G. M., Armstrong, D. S., Carzino, R., Carlin, J. B., Olinsky, A., Robertson, C. F., & Grimwood, K. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.112897 · Cited by 432 · cited 1×
“aeruginosa infections [7,8].”
Using diagnoses to describe populations and predict costs.
Ash, A. S., Ellis, R. P., Pope, G. C., Ayanian, J. Z., Bates, D. W., Burstin, H. R., Iezzoni, L. I., MacKay, E., & Yu, W. (2000) · PubMed Central · Cited by 299
A multi-method assessment of treatment adherence for children with cystic fibrosis
Modi, A. C., Lim, C. S., Yu, N., Geller, D., Wagner, M. H., & Quittner, A. L. (2006) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.03.002 · Cited by 265 · cited 3×
“Reported rates of prescribing TIS to eligible patients are highly variable, ranging from 47-90% [3,10,11].”
BackgroundSelf-citationHealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases
Adamson, D. M. (2008) · Cited by 223
Research works printed but not linked: 6
- Cystic Fibrosis Foundation: Patient Registry: Annual Data Report 2007. 2008, Bethesda, MD
- Quittner AL, Barker DH, Marciel KK, Grimley ME: Cystic fibrosis: A model for drug discovery and patient care. 2009, NY: Guilford Press, 4
- Cystic Fibrosis Foundation: Patients Registry: 2005 Annual Data Report. 2006, Bethesda, MD: Cystic Fibrosis Foundation
- Moskowitz S, Silva S, Mayer-Hamblett N, Pasta D, Mink D, Wagener S, Kostan M, Morgan W: Inhaled Antibiotic Use Among North American Cystic Fibrosis Patients. Annual Meeting of American Thorasic Society. 2007
- Briesacher BA, Sacco P, Fouayzi H, Quittner A: Tobramycin inhaled solution utilization in cystic fibrosis patients in a privately insured US population. 2009, Toronto
- Cystic Fibrosis Foundation: Patient Registry 2001 and 2006 Annual Data Report. 2007, Bethesda, MA
Cited by
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
“In the context of a clinical trial setting, the patients' adherence is generally high, whereas in the real-world, rates of adherence and persistence rates are much lower and the efficacy of a drug can be therefore decreased [149,152].”
BackgroundDevelopment of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
Geller, D. E., Weers, J., & Heuerding, S. (2011) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2010.0855 · Cited by 308
“Also, most patients who are prescribed TIS have far fewer prescription refills than necessary to maintain alternate month cycles.((7)) A variety of reasons may exist for the disconnect between real-world usage of inhaled antibiotics and recommendations in the treatment guidelines.”
Pulmonary medication adherence and health-care use in cystic fibrosis
Quittner, A. L., Zhang, J., Marynchenko, M., Chopra, P. A., Signorovitch, J., Yushkina, Y., & Riekert, K. A. (2014) · Chest · doi:10.1378/chest.13-1926 · Cited by 250
Self-citationSawicki, G. S., Ren, C. L., Konstan, M. W., Millar, S. J., Pasta, D. J., & Quittner, A. L. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.12.009 · Cited by 154
Self-citation
Metadata
- Authors
- Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- University of Miami (US)
- Columbia University (US)
- Corresponding author
- Briesacher, Becky A
- Venue
- BMC Pulmonary Medicine
- Published
- 2011-01-20
- Volume
- 11
- Issue
- 1
- Pages
- 5-5
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC3033861
- OpenAlex
- W1983638164
- Cited by
- 95
- References
- 19
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 9 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 5 · 2015: 12 · 2014: 13 · 2013: 13 · 2012: 2
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- medication adherence, cystic fibrosis, health care utilization, hospitalization risk, prescription drug costs, guideline adherence
- MeSH terms
- Adolescent, Adult, Child, Cystic Fibrosis, Female, Health Services, Hospitalization, Humans, Male, Pseudomonas aeruginosa, Pseudomonas Infections, Tobramycin, Medication Adherence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adherence with tobramycin inhaled solution and health care utilization. https://app.cochat.ai/papers/10.1186/1471-2466-11-5
- The paper
- Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011). Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine. https://doi.org/10.1186/1471-2466-11-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.